MedTrace Logo

Yoga for the Management of HIV-Metabolic Syndromes

NCT00627380 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-07-26

No results posted yet for this study

Summary

We are testing the safety and efficacy of a 16-wk yoga lifestyle intervention on oral glucose tolerance, fasting lipid/lipoprotein levels, body composition, cardiovascular function, quality of life, CD4+ T-cell counts and viral load in HIV-infected men and women with components of The Metabolic Syndrome. We hypothesize that a yoga lifestyle intervention will improve metabolic, anthropometric, cardiovascular disease parameters, and quality of life domains without adversely affecting immune or virologic status in people living with HIV.

Conditions

  • HIV Infections
  • HIV Metabolic Cardiovascular Syndrome
  • HIV Lipodystrophy
  • HIV Metabolic Syndromes
  • Hypertension

Interventions

BEHAVIORAL

Yoga lifestyle intervention

Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.

OTHER

Standard of care

Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Kevin E Yarasheski, PhD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627380 on ClinicalTrials.gov